In addition, advanced HCC patients exhibit higher PD-L1 expression compared with patients with early stage HCC, which make the CD133 protein a reasonable target in CAR-T cell therapy for male patients with advanced HCC, and these patients may also benefit from PD-1/PD-L1 checkpoint blockade therapy. The gene discussed is PROM1; the disease is hepatocellular carcinoma.